Ann: Regulatory progress for VivaGel BV in the US, page-33

I thought one of the problems was that those taking the placebo had an improved result mainly because in less well off areas they went back to the antibiotic because they were sick of the symptoms. Unfortunately it looks like the FDA require another trial. That is why I sold. Just got sick of all the failures and the slow ongoing DEP trails. I just worry that by the time DEP gets to the next phase another technology will over take it (like Immunology) . Anyway good luck to you all and i will remain watching with interest and may return. Unfortunately the opportunity cost of holding this stock and the hubris of current management has made me move on for the time being.